ASCENDING MULTIDOSE CI PHARM STUDY VPA-985 PTS W/CHRONIC CONGESTIVE HEART FAILURE

$32,212M01FY2000RRNIH

University Of Colorado Denver, Aurora CO

Investigators

Linked publications & trials

Paper 39288222 Paper 38991492 Paper 38816203 Paper 38778481 Paper 38741246 Paper 38225212 Paper 38204926 Paper 37978826 Paper 37226675 Paper 37187353 Paper 36933679 Paper 36637994 Paper 36328357 Paper 36280384 Paper 35562076 Paper 35453142 Paper 35300983 Paper 35019976 Paper 35005320 Paper 34970070 Paper 34753805 Paper 34637524 Paper 34587765 Paper 34401721 Paper 34029510 Paper 33707304 Paper 33627633 Paper 33597215 Paper 33305291 Paper 33257283 Paper 33178459 Paper 33168654 Paper 32853853 Paper 32845968 Paper 32841523 Paper 32807060 Paper 32634495 Paper 32634120 Paper 32388179 Paper 32134326 Paper 32128240 Paper 32085906 Paper 31924696 Paper 31898874 Paper 31874800 Paper 31676897 Paper 31558547 Paper 31338998 Paper 31131339 Paper 31028280 Paper 30943964 Paper 30900413 Paper 30864331 Paper 30674623 Paper 30642925 Paper 30482755 Paper 30421851 Paper 30053592 Paper 30026043 Paper 29937138 Paper 29854969 Paper 29847509 Paper 29564978 Paper 29545462 Paper 29461980 Paper 29306517 Paper 29290026 Paper 29218904 Paper 29203126 Paper 29171837 Paper 29159267 Paper 29135907 Paper 29118087 Paper 29086498 Paper 29053861 Paper 28940967 Paper 28734104 Paper 28678345 Paper 28558132 Paper 28460625 Paper 28198537 Paper 28099408 Paper 28095749 Paper 27993381 Paper 27901290 Paper 27839922 Paper 27804265 Paper 27795872 Paper 27747305 Paper 27677166 Paper 27676466 Paper 27603898 Paper 27595918 Paper 27484667 Paper 27471785 Paper 27465756 Paper 27368123 Paper 27367781 Paper 27271190 Paper 27206945

Abstract

VPA-985 is a nonpeptide, orally active competitive vasopressin receptor antagonist, specific for the V2 receptor subtype. This study is designed to evaluate the safety, tolerance, pharmacokinetics and pharmacodynamics of multiple oral doses of VPA-985 in patients with chronic congestive heart failure (CHF). In addition, a preliminary assessment will be made of the changes in the signs and symptoms of excess fluid volume.

View original record on NIH RePORTER →